{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T18:38:22Z","timestamp":1762540702544},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ymgme.2018.01.002","type":"journal-article","created":{"date-parts":[[2018,1,5]],"date-time":"2018-01-05T18:12:50Z","timestamp":1515175970000},"page":"69-75","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Agreement between the results of meta-analyses from case reports and from clinical studies regarding the efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age: An example of case reports meta-analyses as an useful tool for evidence-based medicine in rare diseases"],"prefix":"10.1016","volume":"123","author":[{"given":"Miguel","family":"Sampayo-Cordero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernat","family":"Miguel-Huguet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"Pardo-Mateos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Molt\u00f3-Abad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Mu\u00f1oz-Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"P\u00e9rez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ymgme.2018.01.002_bb0005","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1038\/cti.2015.15","article-title":"Medical case reports in the age of genomic medicine","volume":"4","author":"Cook","year":"2015","journal-title":"Clin. Transl. Immunol."},{"issue":"5","key":"10.1016\/j.ymgme.2018.01.002_bb0010","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJMra1614394","article-title":"Evidence for health decision making - beyond randomized, controlled trials","volume":"377","author":"Frieden","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.ymgme.2018.01.002_bb0015","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1016\/j.ejca.2015.08.004","article-title":"Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome","volume":"51","author":"Monzon","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ymgme.2018.01.002_bb0020","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/1756-0500-7-264","article-title":"The clinical case report: a review of its merits and limitations","volume":"7","author":"Nissen","year":"2014","journal-title":"BMC Res. Notes"},{"issue":"11","key":"10.1016\/j.ymgme.2018.01.002_bb0025","doi-asserted-by":"crossref","first-page":"608","DOI":"10.12998\/wjcc.v2.i11.608","article-title":"Important of case-reports\/series, in rare diseases: using neuroendocrine tumors as an example","volume":"2","author":"Nakamura","year":"2014","journal-title":"World J. Clin. Cases"},{"issue":"2","key":"10.1016\/j.ymgme.2018.01.002_bb0030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ccr3.58","article-title":"Aggregating case reports: a way for the future of evidence-based health care?","volume":"2","author":"Jackson","year":"2014","journal-title":"Clin. Case Rep."},{"key":"10.1016\/j.ymgme.2018.01.002_bb0035","first-page":"2013","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development","volume":"23","author":"Gagnier","year":"2013","journal-title":"BMJ Case Rep."},{"issue":"2","key":"10.1016\/j.ymgme.2018.01.002_bb0040","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ymgme.2017.04.004","article-title":"Efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age. A systematic review and meta-analysis","volume":"121","author":"Perez-Lopez","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.01.002_bb0045","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ymgme.2018.01.002_bb0050","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"issue":"12","key":"10.1016\/j.ymgme.2018.01.002_bb0055","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jclinepi.2011.06.004","article-title":"GRADE guidelines: 9. Rating up the quality of evidence","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"issue":"4","key":"10.1016\/j.ymgme.2018.01.002_bb0060","first-page":"48","article-title":"Phase II design: history and evolution","volume":"3","author":"Rubinstein","year":"2014","journal-title":"Chin. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ymgme.2018.01.002_bb0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/biostatistics\/kxw030","article-title":"Weighted false discovery rate controlling procedures for clinical trials","volume":"18","author":"Benjamini","year":"2017","journal-title":"Biostatistics"},{"issue":"1","key":"10.1016\/j.ymgme.2018.01.002_bb0070","doi-asserted-by":"crossref","first-page":"108","DOI":"10.12891\/ceog1845.2015","article-title":"Successful pregnancy and breastfeeding in a woman with mucopolysaccharidosis type I while receiving laronidase enzyme replacement. Therapy","volume":"42","author":"Castorina","year":"2015","journal-title":"Clin. Exp. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ymgme.2018.01.002_bb0075","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s10545-006-0237-8","article-title":"Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I","volume":"29","author":"Anbu","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2018.01.002_bb0080","first-page":"55","article-title":"Laronidase for treating post-surgical respiratory failure in a patient with type I mucopolysaccharidosis","volume":"36","author":"Velez-Diaz-Pallares","year":"2012","journal-title":"Farm. Hosp."},{"issue":"19","key":"10.1016\/j.ymgme.2018.01.002_bb0085","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1002\/ajmg.a.32294","article-title":"Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression","volume":"146A","author":"Munoz-Rojas","year":"2008","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgme.2018.01.002_bb0090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/8904_2014_316","article-title":"Laronidase replacement therapy and left ventricular function in mucopolysaccharidosis I","volume":"16","author":"Harada","year":"2014","journal-title":"JIMD Rep."},{"issue":"3","key":"10.1016\/j.ymgme.2018.01.002_bb0095","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ymgme.2011.03.016","article-title":"Laronidase replacement therapy improves myocardial function in mucopolysaccharidosis I","volume":"103","author":"Harada","year":"2011","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2018.01.002_bb0100","first-page":"371","article-title":"Sudden vision loss in a mucopolysaccharidosis I patient receiving enzyme replacement therapy","volume":"22","author":"Yosunkaya","year":"2011","journal-title":"Genet. Couns."},{"issue":"4","key":"10.1016\/j.ymgme.2018.01.002_bb0105","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jstrokecerebrovasdis.2010.09.006","article-title":"Scheie syndrome diagnosed after cerebral infarction","volume":"21","author":"Fujii","year":"2012","journal-title":"J. Stroke Cerebrovasc. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2018.01.002_bb0110","doi-asserted-by":"crossref","first-page":"S321","DOI":"10.1007\/s10545-009-1265-y","article-title":"Scheie syndrome: enzyme replacement therapy does not prevent progression of cervical myelopathy due to spinal cord compression","volume":"32","author":"Illsinger","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"issue":"13","key":"10.1016\/j.ymgme.2018.01.002_bb0115","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/ajmg.a.32317","article-title":"Decreased corneal opacity and improved vision in a patient with mucopolysaccharidosis I (hurler-Scheie) treated with enzyme replacement therapy (laronidase, Aldurazyme)","volume":"146A","author":"Caceres-Marzal","year":"2008","journal-title":"Am. J. Med. Genet. A"},{"issue":"6","key":"10.1016\/j.ymgme.2018.01.002_bb0120","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1007\/s10545-005-0211-x","article-title":"Mucopolysaccharidosis I under enzyme replacement therapy with laronidase--a mortality case with autopsy report","volume":"28","author":"Lin","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"issue":"10","key":"10.1016\/j.ymgme.2018.01.002_bb0125","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jfma.2014.05.009","article-title":"Mucopolysaccharidosis I (Scheie syndrome): a rare cause of severe aortic stenosis in a 31-year-old man","volume":"114","author":"Lin","year":"2015","journal-title":"J. Formos. Med. Assoc."},{"issue":"1","key":"10.1016\/j.ymgme.2018.01.002_bb0130","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.ymgme.2018.01.002_bb0135","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/pr.2013.158","article-title":"Immune response to intrathecal enzyme replacement therapy in mucopolysaccharidosis I patients","volume":"74","author":"Vera","year":"2013","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2018.01.002_bb0140","series-title":"Paving the Way for Personalized Medicine: FDA's Role in a New Era of Medical Product Development","year":"2013"},{"issue":"11","key":"10.1016\/j.ymgme.2018.01.002_bb0145","article-title":"Breast cancers are rare diseases-and must be treated as such","volume":"3","author":"Bartlett","year":"2017","journal-title":"NPJ Breast Cancer"},{"issue":"7549","key":"10.1016\/j.ymgme.2018.01.002_bb0150","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/520609a","article-title":"Personalized medicine: time for one-person trials","volume":"520","author":"Schork","year":"2015","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.ymgme.2018.01.002_bb0155","doi-asserted-by":"crossref","first-page":"e0184065","DOI":"10.1371\/journal.pone.0184065","article-title":"Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: a systematic review and meta-analysis","volume":"12","author":"Dornelles","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2018.01.002_bb0160","article-title":"Enzyme replacement therapy with laronidase (Aldurazyme((R))) for treating mucopolysaccharidosis type I","volume":"4","author":"Jameson","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.ymgme.2018.01.002_bb0165","doi-asserted-by":"crossref","first-page":"e0005715","DOI":"10.1371\/journal.pntd.0005715","article-title":"Post-dengue acute disseminated encephalomyelitis: a case report and meta-analysis","volume":"11","author":"Kamel","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ymgme.2018.01.002_bb0170","series-title":"Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration","year":"2011"},{"issue":"34","key":"10.1016\/j.ymgme.2018.01.002_bb0175","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1200\/JCO.2014.55.2984","article-title":"Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer","volume":"32","author":"O'Shaughnessy","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ymgme.2018.01.002_bb0180","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc1704767","article-title":"PD-1 blockade in mediastinal gray-zone lymphoma","volume":"377","author":"Melani","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2018.01.002_bb0185","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ymgmr.2017.01.004","article-title":"Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I","volume":"10","author":"Giugliani","year":"2017","journal-title":"Mol. Genet. Metab. Rep."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217306856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217306856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T21:56:56Z","timestamp":1660255016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719217306856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1096719217306856"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.01.002","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Agreement between the results of meta-analyses from case reports and from clinical studies regarding the efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age: An example of case reports meta-analyses as an useful tool for evidence-based medicine in rare diseases","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}